Published in Antimicrob Agents Chemother on February 01, 1987
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects. Antimicrob Agents Chemother (1988) 1.16
Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1990) 0.90
Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1989) 0.87
Ofloxacin pharmacokinetics in mechanically ventilated patients. Antimicrob Agents Chemother (1991) 0.83
Temafloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1991) 0.82
Enoxacin absorption and elimination characteristics. Clin Pharmacokinet (1989) 0.81
Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections. Antimicrob Agents Chemother (1994) 0.77
Effect of renal impairment on distribution of ofloxacin. Antimicrob Agents Chemother (1990) 0.75
Quinolones in the elderly. Drugs (1995) 0.75
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur J Clin Microbiol (1983) 1.76
Pharmacokinetics of norfloxacin in renal failure. J Antimicrob Chemother (1984) 1.10
Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J (1973) 2.10
Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest (1979) 1.76
Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo. J Natl Cancer Inst (2001) 1.64
High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene (2000) 1.54
Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis (1989) 1.49
[Comparative pharmacokinetics and renal accumulation of the iodized contrast media: ioxitalamic acid, ioxaglic acid and iohexol in the rabbit]. Pathol Biol (Paris) (1987) 1.42
Health-related quality of life in patients with melanoma expressed as utilities and disability weights. Br J Dermatol (2014) 1.42
[Celioscopic cholecystectomy. 2 cases of infectious complications]. Presse Med (1994) 1.40
Adult onset Still's disease and pregnancy. J Rheumatol (1993) 1.39
[Anorectal stenosis caused by suppositories of dextropropoxyphene and paracetamol (Diantalvic)]. Gastroenterol Clin Biol (1986) 1.38
A bioinformatic screen for novel A-I RNA editing sites reveals recoding editing in BC10. Bioinformatics (2005) 1.37
Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function. J Antimicrob Chemother (1983) 1.34
A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet (2001) 1.34
Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int (1992) 1.30
Renal granulomatous sarcoidosis: report of six cases. Nephrol Dial Transplant (1990) 1.26
Gentamicin-induced nephrotoxicity: a cell biology approach. Kidney Int (1980) 1.22
Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother (1978) 1.21
Is presentation of bacteremia in the elderly the same as in younger patients? Am J Med (1996) 1.19
Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron (1991) 1.17
In vivo and in vitro activation and expansion of gammadelta T cells during Listeria monocytogenes infection in humans. Infect Immun (1997) 1.17
Senior-Loken syndrome (nephronophthisis and tapeto-retinal degeneration): a study of 8 cases from 5 families. Clin Nephrol (1976) 1.15
The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis (1983) 1.15
Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother (1988) 1.14
Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother (1984) 1.13
Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. Rev Infect Dis (1983) 1.12
Optimal dose of lignocaine for preventing pain on injection of propofol. Br J Anaesth (1991) 1.12
Supercontinuum generation system for optical coherence tomography based on tapered photonic crystal fibre. Opt Express (2006) 1.12
Pharmacokinetics of norfloxacin in renal failure. J Antimicrob Chemother (1984) 1.10
A new essential gene of the 'minimal genome' affecting cell division. Biochimie (2000) 1.10
Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther (1979) 1.05
Karyomegalic interstitial nephritis. Am J Kidney Dis (1996) 1.03
Host sequences flanking the human T-cell leukemia virus type 1 provirus in vivo. J Virol (2000) 1.01
[Treatment of anuria with furosemide]. Nouv Presse Med (1972) 1.00
Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther (1989) 1.00
Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients. Eur J Clin Pharmacol (1989) 1.00
Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1981) 0.99
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Clin Pharmacokinet (1990) 0.99
Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1988) 0.98
[Should adult nephrotic syndrome secondary to idiopathic extramembranous glomerulonephritis be treated? An approach by decisional analysis]. Nephrologie (1992) 0.97
Computer-assisted access to the kidney. Int J Med Robot (2005) 0.96
Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother (1980) 0.96
Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1980) 0.96
Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients. J Antimicrob Chemother (1976) 0.96
The cytogenetic dosimetry of recent accidental overexposure. Cell Mol Biol (Noisy-le-grand) (2001) 0.96
Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1995) 0.95
Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol (1992) 0.95
Prediction of creatinine clearance from serum creatinine concentration based on lean body mass. Clin Pharmacol Ther (1981) 0.95
Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int (1981) 0.94
Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy (1979) 0.94
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer (1980) 0.94
Group R streptococci: wild boars as a second reservoir. Scand J Infect Dis (1985) 0.93
Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function. Antibiot Chemother (1971) (1978) 0.93
[Massive poisoning by African bee stings]. Presse Med (1998) 0.93
[Rheumatologial manifestations of bacterial endocarditis]. Rev Rhum Mal Osteoartic (1974) 0.93
RBC membrane adenosine triphosphatase activities in patients with major affective disorders. Arch Gen Psychiatry (1983) 0.92
Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin-and glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1993) 0.92
Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. J Antimicrob Chemother (1984) 0.92
Effect of gravity on human spontaneous 10-Hz electroencephalographic oscillations during the arrest reaction. Brain Res (2006) 0.91
Escherichia coli RNA degradosome. Methods Enzymol (2001) 0.91
Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant (1997) 0.91
Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1990) 0.90
Pharmacokinetics of dibekacin in normal subjects and in patients with renal failure. J Antimicrob Chemother (1980) 0.90
Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis (1988) 0.90
Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Chemotherapy (1983) 0.90
Extracellular protease activity of different Pseudomonas strains: dependence of proteolytic activity on culture conditions. J Appl Microbiol (2005) 0.89
Antibiotic nephrotoxicity. Chemioterapia (1984) 0.89
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother (1992) 0.89